CN110064056B - 细胞穿透性肽、包含该肽的缀合物、及包含该缀合物的组合物 - Google Patents

细胞穿透性肽、包含该肽的缀合物、及包含该缀合物的组合物 Download PDF

Info

Publication number
CN110064056B
CN110064056B CN201910049089.3A CN201910049089A CN110064056B CN 110064056 B CN110064056 B CN 110064056B CN 201910049089 A CN201910049089 A CN 201910049089A CN 110064056 B CN110064056 B CN 110064056B
Authority
CN
China
Prior art keywords
peptide
conjugate
cell
leu
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201910049089.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN110064056A (zh
Inventor
金商在
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GemVax and Kael Co Ltd
Original Assignee
GemVax and Kael Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GemVax and Kael Co Ltd filed Critical GemVax and Kael Co Ltd
Publication of CN110064056A publication Critical patent/CN110064056A/zh
Application granted granted Critical
Publication of CN110064056B publication Critical patent/CN110064056B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/06—Enzymes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/10—General cosmetic use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/86—Products or compounds obtained by genetic engineering
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Birds (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201910049089.3A 2012-09-19 2013-09-17 细胞穿透性肽、包含该肽的缀合物、及包含该缀合物的组合物 Active CN110064056B (zh)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
KR20120104144 2012-09-19
KR10-2012-0104144 2012-09-19
KR10-2012-0109216 2012-09-28
KR20120109216 2012-09-28
KR10-2013-0017046 2013-02-18
KR20130017169 2013-02-18
KR20130017046 2013-02-18
KR10-2013-0017169 2013-02-18
CN201380057722.4A CN104768967B (zh) 2012-09-19 2013-09-17 细胞穿透性肽、包含该肽的缀合物、及包含该缀合物的组合物
PCT/KR2013/008445 WO2014046481A1 (ko) 2012-09-19 2013-09-17 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380057722.4A Division CN104768967B (zh) 2012-09-19 2013-09-17 细胞穿透性肽、包含该肽的缀合物、及包含该缀合物的组合物

Publications (2)

Publication Number Publication Date
CN110064056A CN110064056A (zh) 2019-07-30
CN110064056B true CN110064056B (zh) 2022-10-28

Family

ID=50341702

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201910049089.3A Active CN110064056B (zh) 2012-09-19 2013-09-17 细胞穿透性肽、包含该肽的缀合物、及包含该缀合物的组合物
CN201910048425.2A Active CN110028554B (zh) 2012-09-19 2013-09-17 细胞穿透性肽、包含该肽的缀合物、及包含该缀合物的组合物
CN201380057722.4A Active CN104768967B (zh) 2012-09-19 2013-09-17 细胞穿透性肽、包含该肽的缀合物、及包含该缀合物的组合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201910048425.2A Active CN110028554B (zh) 2012-09-19 2013-09-17 细胞穿透性肽、包含该肽的缀合物、及包含该缀合物的组合物
CN201380057722.4A Active CN104768967B (zh) 2012-09-19 2013-09-17 细胞穿透性肽、包含该肽的缀合物、及包含该缀合物的组合物

Country Status (8)

Country Link
US (1) US9631184B2 (enExample)
EP (1) EP2899199B1 (enExample)
JP (1) JP6510410B2 (enExample)
KR (1) KR102201430B1 (enExample)
CN (3) CN110064056B (enExample)
ES (1) ES2743919T3 (enExample)
TW (1) TWI598441B (enExample)
WO (1) WO2014046481A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2850097B1 (en) 2012-05-11 2018-07-25 KAEL-GemVax Co.,Ltd Anti-inflammatory peptides and composition comprising the same
EP2875826B1 (en) 2012-05-11 2017-08-23 KAEL-GemVax Co.,Ltd Composition for preventing or treating sepsis
ES2981865T3 (es) 2012-07-11 2024-10-10 Gemvax & Kael Co Ltd Conjugado que comprende un péptido de penetración celular y composiciones que comprenden el mismo
US20150125438A1 (en) 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
US9572900B2 (en) 2012-09-19 2017-02-21 Gemvax & Kael Co., Ltd. Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
EP2899200B1 (en) 2012-09-19 2020-05-06 Gemvax & Kael Co., Ltd. Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
CN105263508B (zh) 2013-04-19 2019-10-25 珍白斯凯尔有限公司 治疗和预防缺血性损伤的组合物
WO2014196841A1 (en) 2013-06-07 2014-12-11 Kael-Gemvax Co., Ltd. Biological markers useful in cancer immunotherapy
ES2808076T3 (es) 2013-06-21 2021-02-25 Gemvax & Kael Co Ltd Regulador de la secreción hormonal, composición que lo contiene y procedimiento para controlar la secreción hormonal mediante su uso
CN105531284B (zh) * 2013-07-12 2021-03-23 珍白斯凯尔有限公司 细胞穿透肽和包含其的缀合物
PH12018502667A1 (en) 2013-10-23 2022-11-14 Gemvax And Kael Co Ltd Composition for treating and preventing benign prostatic hyperplasia
WO2015076621A1 (ko) 2013-11-22 2015-05-28 주식회사 카엘젬백스 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
CN105939723B (zh) 2013-12-17 2020-02-28 珍白斯凯尔有限公司 前列腺癌治疗用组合物
KR102373603B1 (ko) 2014-04-11 2022-03-14 주식회사 젬백스앤카엘 섬유증 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
US10662223B2 (en) 2014-04-30 2020-05-26 Gemvax & Kael Co., Ltd. Composition for organ, tissue, or cell transplantation, kit, and transplantation method
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
JP6751097B2 (ja) 2015-02-27 2020-09-02 ジェムバックス アンド カエル カンパニー，リミティド 聴力損傷予防用ペプチド及びそれを含む組成物
JP7000161B2 (ja) 2015-05-26 2022-01-19 ジェムバックス アンド カエル カンパニー，リミティド 新規ペプチド及びこれを含む組成物
CN107847551B (zh) 2015-07-02 2022-02-08 珍白斯凯尔有限公司 具有抗病毒作用的肽和包含其的组合物
CN113476589A (zh) * 2015-11-03 2021-10-08 珍白斯凯尔有限公司 肽在制造用于治疗神经退行性疾病的组合物中的用途
KR101661912B1 (ko) 2016-01-29 2016-10-04 (주)넥스젠바이오텍 녹색형광단백질-인간 상피세포재생인자 융합단백질을 유효성분으로 포함하는 주름 개선 및 항노화 화장료 조성물
CN109328068A (zh) 2016-04-07 2019-02-12 珍白斯凯尔有限公司 具有增加端粒酶活性和延长端粒的效果的肽以及包含该肽的组合物
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
US20210386788A1 (en) 2018-10-24 2021-12-16 Obsidian Therapeutics, Inc. Er tunable protein regulation
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
US20230181681A1 (en) * 2020-05-08 2023-06-15 Industry Academic Cooperation Foundation, Hallym University Peptide for suppressing coronavirus and use thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69723531T3 (de) * 1996-10-01 2012-09-06 Geron Corp. Katalytische Untereinheit der menschlichen Telomerase
US6610839B1 (en) * 1997-08-14 2003-08-26 Geron Corporation Promoter for telomerase reverse transcriptase
US7030211B1 (en) * 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
GB0112342D0 (en) * 2001-05-21 2001-07-11 Norsk Hydro As Polypeptides
AU2002363231A1 (en) * 2001-10-29 2003-05-12 Baylor College Of Medicine Human telomerase reverse transcriptase as a class-ii restricted tumor-associated antigen
US7294708B2 (en) * 2002-05-31 2007-11-13 Beijing Institute Of Biotechnology Telomerase reverse transcriptase fragments and uses thereof
AU2006325030B2 (en) 2005-12-16 2012-07-26 Cellectis Cell penetrating peptide conjugates for delivering nucleic acids into cells
KR100859972B1 (ko) 2006-02-20 2008-09-25 이화여자대학교 산학협력단 막투과 단백질 도메인 펩타이드
AU2008211854C1 (en) * 2007-01-29 2014-01-23 Procell Therapeutics Inc. Novel macromolecule transduction domains and methods for identification and uses thereof
EP1994942A1 (en) * 2007-05-25 2008-11-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical compositions comprising telomerase, and uses thereof
WO2010003520A2 (en) * 2008-06-16 2010-01-14 Genovax S.R.L. Anti-tumor immunotherapy
ES2334315B1 (es) * 2008-07-29 2011-02-28 Universitat Pompeu Fabra Peptidos con capacidad de penetracion celular y sus usos.
US20110318380A1 (en) * 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
KR101169030B1 (ko) 2009-01-21 2012-07-26 애니젠 주식회사 신규한 세포막 투과 도메인 및 이를 포함하는 세포내 전달 시스템
AU2010250452B2 (en) 2009-05-20 2014-06-05 Toray Industries, Inc. Cell membrane-permeable peptides
EP2536830B1 (en) 2010-02-16 2019-07-17 Ultimovacs AS Polypeptides
KR101263212B1 (ko) 2010-05-28 2013-05-10 성신여자대학교 산학협력단 신규한 세포막 투과성 펩타이드 및 그의 용도
WO2011150493A1 (en) * 2010-05-30 2011-12-08 The Governing Council Of The University Of Toronto Mitochondrial penetrating peptides as carriers for antimicrobials
KR101348284B1 (ko) 2010-09-09 2014-01-03 주식회사 나이벡 인간 유래 세포 투과성 펩타이드와 생리활성 펩타이드 결합체 및 그 용도
EP2850097B1 (en) 2012-05-11 2018-07-25 KAEL-GemVax Co.,Ltd Anti-inflammatory peptides and composition comprising the same
ES2981865T3 (es) 2012-07-11 2024-10-10 Gemvax & Kael Co Ltd Conjugado que comprende un péptido de penetración celular y composiciones que comprenden el mismo
EP2899200B1 (en) 2012-09-19 2020-05-06 Gemvax & Kael Co., Ltd. Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
US9572900B2 (en) 2012-09-19 2017-02-21 Gemvax & Kael Co., Ltd. Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
KR101778244B1 (ko) * 2014-05-13 2017-09-26 한양대학교 산학협력단 세포 투과성 펩티드 및 이를 이용한 생물학적 활성 물질의 전달방법

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Cell-Penetrating Peptides and Peptide Nucleic Acid-Coupled MRI Contrast Agents: Evaluation of Cellular Delivery and Target Binding;Ritu Mishra等;《Bioconjugate Chem》;20090929;第1860-1868页 *
Humanized telomeres and an attempt to express a functional human telomerase in yeast;Amadou Bah等;《Nucleic Acids Research》;20040326;第1917-1927页 *
Telomerase Peptide Vaccination in NSCLC:A Phase II Trial in Stage III Patients Vaccinated after Chemoradiotherapy and an 8-year Update on a Phase I/II Trial;Paal Fr.Brunsvig等;《Clinical Cancer Research》;20111101;第17卷(第21期);第6847-6857页 *

Also Published As

Publication number Publication date
US9631184B2 (en) 2017-04-25
JP6510410B2 (ja) 2019-05-08
TWI598441B (zh) 2017-09-11
KR20150060763A (ko) 2015-06-03
ES2743919T3 (es) 2020-02-21
CN104768967B (zh) 2019-02-15
EP2899199B1 (en) 2019-07-03
WO2014046481A1 (ko) 2014-03-27
CN110064056A (zh) 2019-07-30
US20160002613A1 (en) 2016-01-07
CN110028554B (zh) 2023-04-07
JP2015530404A (ja) 2015-10-15
CN104768967A (zh) 2015-07-08
EP2899199A4 (en) 2016-06-15
CN110028554A (zh) 2019-07-19
EP2899199A1 (en) 2015-07-29
TW201416448A (zh) 2014-05-01
KR102201430B1 (ko) 2021-01-12

Similar Documents

Publication Publication Date Title
CN110064056B (zh) 细胞穿透性肽、包含该肽的缀合物、及包含该缀合物的组合物
JP7742390B2 (ja) 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
US20240181090A1 (en) Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
CN104822698B (zh) 细胞穿透肽以及包含该肽的缀合物和组合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant